Randomized Double-Blind Placebo Controlled Phase II Study of a Galectin-3 Inhibitor (GB1211) and Pembrolizumab Versus Pembrolizumab and Placebo in Patients With Metastatic Melanoma and Head and Neck Squamous Cell Carcinoma
Latest Information Update: 13 Mar 2025
At a glance
- Drugs Pembrolizumab (Primary) ; Selvigaltin (Primary)
- Indications Carcinoma; Head and neck cancer; Malignant melanoma; Squamous cell cancer
- Focus Therapeutic Use
- 07 Oct 2024 According to a Galecto Biotech media release, this trial was initiated and enrolled its first patient in the second quarter of 2024.
- 01 May 2024 According to a Galecto Biotech media release, the early data of this study could be available as early as 2025.
- 01 May 2024 According to a Galecto Biotech media release, the first patient of this study has been enrolled and dosed.